We are live on
!
Find out more
PCM
Piermont Capital Management Portfolio holdings
AUM
$211M
1-Year Est. Return
8.09%
This Fund
S&P 500
This Quarter
Est. Return
+7.52%
1 Year Est. Return
-8.09%
3 Year Est. Return
+33.18%
5 Year Est. Return
+53.13%
10 Year Est. Return
–
AUM
$422M
AUM Growth
+$36M
(+9.3%)
Cap. Flow
+$16.2M
Cap. Flow
% of AUM
3.84%
Top 10 Holdings %
Top 10 Hldgs %
10%
Holding
310
New
74
Increased
75
Reduced
64
Closed
65
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Murphy USA
MUSA
|
+$3.73M |
| 2 |
Spire
SR
|
+$3.35M |
| 3 |
Strategy Inc
MSTR
|
+$3.32M |
| 4 |
Interface
TILE
|
+$3.31M |
| 5 |
RPT
RPT Realty Common Shares of Beneficial Interest (MD)
RPT
|
+$3.18M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALE
Allete
ALE
|
+$3.98M |
| 2 |
Sanmina
SANM
|
+$3.55M |
| 3 |
Portland General Electric
POR
|
+$3.55M |
| 4 |
Trustmark
TRMK
|
+$3.48M |
| 5 |
Northwest Natural Holdings
NWN
|
+$3.37M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 18.89% |
| 2 | Industrials | 17.05% |
| 3 | Technology | 12.96% |
| 4 | Consumer Discretionary | 12.85% |
| 5 | Real Estate | 9.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
226
Kohl's
KSS
$2.19B
| $586K | 0.14% |
13,400
| – | – |
|
|
TIF
227
DELISTED
Tiffany & Co.
TIF
| $569K | 0.13% |
7,840
| – | – |
|
|
RGLS
228
DELISTED
Regulus Therapeutics
RGLS
| $548K | 0.13% |
1,384
+118
| +9% | +$48.5K |
|
|
PETX
229
DELISTED
Aratana Therapeutics, Inc.
PETX
| $541K | 0.13% |
+57,834
| New | +$480K |
|
230
Best Buy
BBY
$17.3B
| $539K | 0.13% |
14,110
| – | – |
|
231
Nektar Therapeutics
NKTR
$2.58B
| $534K | 0.13% |
2,072
-1,933
| -48% | -$498K |
|
|
IPXL
232
DELISTED
Impax Laboratories, Inc.
IPXL
| $534K | 0.13% |
+22,540
| New | +$606K |
|
|
TRVN
233
DELISTED
Trevena, Inc.
TRVN
| $529K | 0.13% |
+125
| New | +$536K |
|
234
Karyopharm Therapeutics
KPTI
$48M
| $507K | 0.12% |
+3,472
| New | +$417K |
|
235
Amphastar Pharmaceuticals
AMPH
$916M
| $506K | 0.12% |
+26,663
| New | +$484K |
|
|
SPR
236
DELISTED
Spirit AeroSystems
SPR
| $499K | 0.12% |
11,200
| – | – |
|
237
ANI Pharmaceuticals
ANIP
$1.78B
| $490K | 0.12% |
+7,380
| New | +$462K |
|
|
AKRX
238
DELISTED
Akorn Inc
AKRX
| $483K | 0.11% |
+17,730
| New | +$525K |
|
|
CBM
239
DELISTED
Cambrex Corporation
CBM
| $431K | 0.1% |
+9,690
| New | +$471K |
|
240
Fluor
FLR
$7.96B
| $430K | 0.1% |
8,380
| – | – |
|
241
Exelixis
EXEL
$13.4B
| $400K | 0.09% |
+31,270
| New | +$338K |
|
242
Steel Dynamics
STLD
$37.6B
| $382K | 0.09% |
15,270
| – | – |
|
|
ANDV
243
DELISTED
Andeavor
ANDV
| $368K | 0.09% |
4,630
| – | – |
|
244
Ameren
AEE
$30.1B
| $357K | 0.08% |
7,250
+1,600
| +28% | +$81.6K |
|
245
Novavax
NVAX
$1.31B
| $330K | 0.08% |
7,939
+668
| +9% | +$86.2K |
|
|
ALE
246
DELISTED
Allete
ALE
| – | – |
-61,581
| Closed | -$3.98M |
|
|
ALEX
247
DELISTED
Alexander & Baldwin
ALEX
| – | – |
-73,855
| Closed | -$2.67M |
|
248
ArcBest
ARCB
$3.08B
| – | – |
-97,740
| Closed | -$1.59M |
|
249
ATN International
ATNI
$492M
| – | – |
-16,147
| Closed | -$1.26M |
|
|
DCH
250
Dauch Corp
DCH
$1.51B
| – | – |
-41,187
| Closed | -$596K |
|
Similar funds
WAM
GIM
PPC
MA
PC
HCG
WA
VAM
Piermont Capital Management's Q3 2016 Portfolio in Review
As of Q3 2016, Piermont Capital Management held 310 positions worth $422M, up 9.3% from $386M the previous quarter. Its ten largest holdings account for 10% of the portfolio.
Piermont Capital Management deployed $16.2M of net new capital in Q3 2016, opening 74 new positions and adding to 75 existing holdings. Its largest new stake was Murphy USA: 49,881 shares worth $3.56M.
By sector, the portfolio is most concentrated in Financials at 19% of assets, up from 18% a quarter earlier, followed by Industrials and Technology.
On the sell side, the largest reduction was Anika Therapeutics, an estimated $1.15M trimmed.
- Piermont Capital Management's largest Q3 2016 buy was Murphy USA: 49,881 shares worth $3.56M.
- Piermont Capital Management added most to Spire in Q3 2016, an estimated $3.35M increase.
- Piermont Capital Management's biggest Q3 2016 reduction was Anika Therapeutics, cutting an estimated $1.15M.
- Piermont Capital Management fully exited Allete in Q3 2016, selling an estimated $3.98M.
- Piermont Capital Management's ten largest holdings make up 10% of its $422M portfolio in Q3 2016.
- Piermont Capital Management opened 74 new positions and closed 65 in Q3 2016.
- Piermont Capital Management's portfolio value rose 9.3% quarter-over-quarter to $422M.
Based on Piermont Capital Management's 13F filing for Q3 2016, filed 10 Nov 2016.